1,721,018 research outputs found
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors
No full textReceptors for luteinizing hormone-releasing hormone (LHRH) can be utilized for targeted chemotherapy of cytotoxic LHRH analogs. The compound AEZS-108 (previously AN-152) consists of [D-Lys?]LHRH linked to doxorubicin. The objectives of this first study in humans with AESZ-108 were to determine the maximum tolerated dose and to characterize the dose-limiting toxicity, pharmacokinetics, preliminary efficacy, and hormonal effects
Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)
No full textObjectives. To evaluate the activity and toxicity of AEZS-108 (Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors. Methods. Women with epithelial ovarian, fallopian tube or primary peritoneal cancer, expressing LHRH receptors were eligible for this trial, when they had progression during treatment with a platinum based regimen or within 6 months after receiving a platinum based regimen and a previous taxane treatment At least one measurable target lesion (RECIST) or CA-125 levels higher than twice the upper limit of normal range (GCIG-criteria) were required. Patients received AEZS-108 (267 mg/m(2) equimolar to 76.8 mg/m(2) of free doxorubicin) every 3 weeks as a two hour i.v. infusion. Results. Fifty-five of 59 (93%) of ovarian cancer samples screened expressed LHRH receptors. 42 patients were enrolled in this study and received at least 1 infusion of AEZS-108 (ITT population). Of these 42 patients 6 (143%) had a partial response, 16 (38%) stable disease, 16 (38%) progressive disease and 4 patients were not evaluable. Median time to progression was 12 weeks (95% CI: 8-20 weeks), and median overall survival was 53 weeks (95% CI: 39-73 weeks). Toxicity profile was favorable. Conclusion. AEZS-108 has a clinical activity in platinum refractory/resistant ovarian cancer which, seems to be comparable to that of pegylated liposomal doxorubicin or to topotecan. Toxicity was comparably low. These data support the concept of a targeted chemotherapy for tumors expressing LHRH receptors. (C) 2014 Elsevier Inc. All rights reserved
Immunhistochemische Analyse der Immuncheckpoints PD-1/PD-L1 und deren prognostische Bedeutung beim tripel-negativen Mammakarzinom
Get PDFDie prognostische Bedeutung der Expression von Acid-Ceramidase (ASAH1) und Sphingosin-Kinase 1 (SPHK1) bei Patientinnen mit Ovarialkarzinom
No full text
Innere Hernien nach laparoskopischen Roux-en-Y Rekonstruktionen bei Patienten mit morbider Adipositas
Get PDF
Establishment of a chlamydial urogenital tract infection model for investigation of novel anti-chlamydial substances in vivo
No full text
- …
